SGLT2 inhibitors reduce epicardial adipose tissue more than GLP ‐1 agonists or exercise interventions in patients with type 2 diabetes mellitus and/or obesity: A systematic review and network meta‐analysis

Documents similaires

• Dapagliflozin reduces epicardial adipose tissue in patients with heart failure and type 2 diabetes
  par: Mohmmad Alghamdi, et autres
  Publié: (2025)
• Cardiorenal outcomes and mortality with GLP ‐1 receptor agonists combined with SGLT2 inhibitors in type 2 diabetes: An updated systematic review and meta‐analysis
  par: João Sérgio Neves, et autres
  Publié: (2025)
• Efficacy and safety of GLP ‐1 receptor agonists and SGLT2 inhibitors as adjuncts to insulin in type 1 diabetes: Systematic review and meta‐analysis
  par: Sama M. Abdel‐Rahman, et autres
  Publié: (2026)
• Adherence to GLP ‐1 receptor agonists and SGLT2 inhibitors by out‐of‐pocket spending among Medicare beneficiaries with diabetes
  par: Nicklas S. Klepser, et autres
  Publié: (2025)
• The importance of treatment sequencing with SGLT2 inhibitors and GLP ‐1 receptor agonists combination for kidney function preservation in type 2 diabetes
  par: Mario Luca Morieri, et autres
  Publié: (2026)